<SEC-DOCUMENT>0001193125-20-141582.txt : 20200513
<SEC-HEADER>0001193125-20-141582.hdr.sgml : 20200513
<ACCEPTANCE-DATETIME>20200513160102
ACCESSION NUMBER:		0001193125-20-141582
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200513
FILED AS OF DATE:		20200513
DATE AS OF CHANGE:		20200513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		20873127

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d895561d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of May 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39173</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 802,
West Tower, OmniVision, 88 Shangke Road, Pudong District </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 201210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):________________ </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">I-MAB</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;13, 2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit Index </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 99.1&#151;Press Release </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d895561dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g895561g0513135858091.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>First Patient Dosed with <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> CD73 Antibody TJD5 in Phase
1/2 Clinical Trial in China for </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Advanced Solid Tumors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SHANGHAI, China, and ROCKVILLE, MD., May&nbsp;13, 2020 &#151; <FONT STYLE="white-space:nowrap">I-Mab</FONT> (NASDAQ: IMAB), a clinical stage biopharmaceutical
company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announced that the first patient has been dosed in a Phase 1/2 clinical
study in China to evaluate <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> proprietary CD73 antibody TJD5, also known as TJ004309, in patients with advanced solid tumors (CTR20200445; NCT04322006). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;It&#146;s exciting news that the TJD5 study has been initiated in China. TJD5 represents a promising novel compound targeting the cancer
microenvironment. This could bring new hopes to the patients if safety and efficacy could be demonstrated,&#148; said Professor <FONT STYLE="white-space:nowrap">Yi-Long</FONT> Wu, Tenured Professor of Guangdong Lung Cancer Institute, Guangdong
Provincial People&#146;s Hospital and Guangdong Academy of Medical Sciences, South China University of Technology, Chair of Chinese Thoracic Oncology Group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Phase 1/2 study is a multicenter, open-label, dose escalation and cohort expansion study, which will evaluate safety, tolerability, pharmacokinetics,
pharmacodynamics and efficacy of TJD5, and determine a recommended dose for further clinical studies of its efficacy and safety as a single agent and in combination with standard dose of toripalimab (TUOYI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> ) in patients with advanced or metastatic cancers who are refractory to or intolerant of all available therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased to advance TJD5 into the clinical study in China and are committed to realizing the potential of TJD5 as a next-generation
immuno-oncology agent,&#148; said Dr.&nbsp;Joan Shen, M.D., Ph.D., CEO of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> &#147;We have been able to accelerate the Phase 1/2 trial in China by leveraging data from the ongoing Phase 1 clinical study of
TJD5 in the United States, which is a testament to our global clinical development capabilities and well-executed pipeline strategies.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The
low response rates to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> inhibitor treatments in cancer patients remain a significant unmet clinical need. As CD73 is widely expressed in various cancers, we
hope the combination therapy of TJD5 with toripalimab could provide a potential new transformational treatment option for patients in need,&#148; Dr.&nbsp;Shen added. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> entered into a research collaboration with Junshi Biosciences (HKEX:01877) in September 2019 to evaluate TJD5 in
combination with toripalimab (TUOYI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) for the treatment of patients with cancers in China. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g895561g0513135858091.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About TJD5 (TJ004309) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TJD5 is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine
monophosphate (AMP) to adenosine. Adenosine binds adenosine A<SUB STYLE="font-size:85%; vertical-align:bottom">2A</SUB> and A<SUB STYLE="font-size:85%; vertical-align:bottom">2B</SUB> receptors on immune cells and inhibits immune responses directed
against tumors. TJD5 is expected to suppress the immunosuppressive tumor micro-environment and to work in concert with other cancer therapies such as <FONT STYLE="white-space:nowrap">PD-1</FONT> and <FONT STYLE="white-space:nowrap">PD-L1</FONT>
antibodies. TJD5 exerts anti-tumor activities through a unique intra-dimerization mechanism to completely inhibit the activity of the targeted enzyme as evident in preclinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TJD5 is also in a Phase 1 clinical trial in the US to assess the tolerability and preliminary efficacy as a single agent and in combination with atezolizumab
(TECENTRIQ<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody marketed by Roche, in patients with advanced solid tumors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> (NASDAQ: IMAB) is a dynamic, global biotech company exclusively focused on developing novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> mission is to bring transformational medicines to patients through innovation. <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> innovative pipeline of more than 10 clinical and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates is driven by the Company&#146;s <FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(Proof-of-Concept)</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> development strategies through internal R&amp;D and
global partnerships. The Company is on track to become a fully integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company with cutting-edge discovery platforms, proven <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development expertise, and world-class GMP manufacturing capabilities. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has offices in China and the United States. For more information, please
visit <U><FONT STYLE="white-space:nowrap">http://ir.i-mabbiopharma.com</FONT></U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> forward looking
statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes certain disclosures which contain &#147;forward-looking statements.&#148; You can identify forward-looking
statements because they contain words such as &#147;anticipate&#148; and &#147;expected.&#148; Forward-looking statements are based on <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> current expectations and assumptions. Because forward-looking
statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor
guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in filings with the U.S. Securities and Exchange Commission. <FONT
STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please contact: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jielun Zhu, CFO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <FONT STYLE="white-space:nowrap">jielun.zhu@i-mabbiopharma.com</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6057 8000 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g895561g0513135858091.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gigi Feng, Vice President and Global Head of Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <FONT STYLE="white-space:nowrap">gigi.feng@i-mabbiopharma.com</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6057 8000 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Burns McClellan, Inc. (Americas and Europe) </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steve Klass
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> sklass@burnsmc.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office line: +1 212 213 0006 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Piacente Group, Inc. (Asia)
</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emilie Wu </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> emilie@thepiacentegroup.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office line: + 86 21 6039 8363 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g895561g0513135858091.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g895561g0513135858091.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !) ,D# 2(  A$! Q$!_\0
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J%+8****ZR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
